- Bruker posted better-than-expected second quarter results, as the company is seeing a broad recovery across its academic, applied, clinical, and industrial end-markets.
- Project Accelerate 2.0 is the next iteration of an already-successful program to refocus the company's core technologies and capabilities on growth markets in life sciences and diagnostics.
- Although Bruker's valuation isn't that appealing on a DCF basis, that's normal for the sector, and the valuation isn't unreasonable on the basis of near-term revenue growth and margin leverage.
For further details see:
Bruker's Renewed Focus On Growth Has Lit A Fire Under The Shares